GPCR
Structure Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.01
+4.41%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -6.2%
- EBIT
- -17.5%
- EPS
- +2.9%
- Free cash flow
- -36.7%
- Operating cash flow
- -35.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +29.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -15.0%
- EBIT
- -81.7%
- Net income
- -15.2%
- EPS
- -2.6%
- Free cash flow
- -91.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026